Fidelity Disruptive Medicine Fund (FMEDX) Research
The fund primarily directs at least 80% of its total assets into companies that are leading advancements in the medical sector. Its core investments largely consist of equity instruments. According to the Adviser, "disruptive medicine" companies encompass, but are not limited to, those engaged in fields such as robotic surgical procedures, gene therapy, genomic research, treatments for rare conditions, cutting-edge medical devices and apparatus, immunotherapy, digital healthcare platforms, and initiatives promoting consumer well-being. It is important to note that this fund operates as a non-diversified portfolio.
Market snapshot
- Symbol
- FMEDX
- Price
- $11.28
- Day change
- -0.18%
- Market cap
- $43.2M
- 52-week range
- 10.96-11.6
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- Bernzott U.S. Small Cap Value Fund (BSCVX)
- BNY Mellon Diversified Emerging Markets Fund (DBECX)
- Fidelity Simplicity RMD 2020 Fund (FIRWX)
- Fidelity Disruptive Communications Fund (FNETX)
- Fidelity Disruptive Finance Fund (FNTEX)
- The New Ireland Fund, Inc. (IRL)
- Neuberger Berman New York Municipal Fund, Inc. (NBO)
- Vivaldi Multi-Strategy Fund (OMOAX)
Open Fidelity Disruptive Medicine Fund (FMEDX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.